The Institute for Clinical and Economic Review (ICER) on Thursday, May 2, suggested in a recently-released evidence report that Novartis’ siponimod, which is used in the treatment of secondary progressive multiple sclerosis (SPMS), “far exceeds” common quality-adjusted life year and life year gained cost thresholds.
According to a press release, the report will be discussed at the May 23 meeting of the Midwest Comparative Comparative Effectiveness Public Advisory Council in Rosemont, Illinois.
“While the FDA did not approve siponimod for non-active SPMS, we felt it remained important to review the data assessing siponimod’s potential benefit in all SPMS, including in those patients for whom disease mainly involves progression rather than relapses,” ICER CMO David Rind said in a statement.
To read the evidence report on ICER’s website, click here.
